"Imugene’s PFS HR was comparable to the landmark Genentech/Roche registrational ToGA study
(PFS HR of 0.71), which also examined the effect of Herceptin plus chemotherapy versus SOC
chemotherapy alone in advanced HER-2 positive gastric cancer."
So the benefit is the same as Herceptin, but my understanding is that the safety / side effects of Herceptin can be nasty. Can anyone elaborate?
"Imugene’s PFS HR was comparable to the landmark Genentech/Roche...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.001(1.79%) |
Mkt cap ! $418.9M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.7¢ | 5.4¢ | $461.9K | 8.347M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1082545 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 603058 | 6 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |